---
title: "Nexgel | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 3.69 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296104653.md"
datetime: "2026-08-17T12:17:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296104653.md)
  - [en](https://longbridge.com/en/news/296104653.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296104653.md)
generator: "portal-rs"
---

# Nexgel | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 3.69 M

Revenue: As of FY2026 Q2, the actual value is USD 3.69 M, missing the estimate of USD 4.315 M.

#### Q2 2026 Financial Highlights

NEXGEL, Inc. reported total revenue of $3.69 million for the quarter ended June 30, 2026.The Company recorded a net loss of -$2.87 million for the same period.

#### Specific Items Affecting Net Loss

The reported net loss included $756,554 for BioNX intangible asset amortization, $273,710 for one-time transaction-related expenses, and $144,495 associated with the strategic recall of all SilverSeal inventory from Amazon.

#### Operational Metrics

As of the reporting period, NEXGEL, Inc. had a current BioNX Surgical backlog of approximately $795,000, attributed to ongoing supply chain challenges impacting product availability.The integration of acquired businesses and associated revenue ramp have progressed more slowly than originally anticipated.

#### Cash Position

As of June 30, 2026, NEXGEL, Inc. held approximately $710,000 of restricted cash related to its prior transaction with ATW Partners.Since quarter end, these funds have been released and returned to the Company, and the business relationship with ATW has concluded.

#### Outlook and Strategic Initiatives

NEXGEL, Inc. undertook a SilverSeal inventory recall to support the product’s launch into the hospital market beginning in August, which management believes represents a significant growth opportunity with potential for increased sales volume and higher gross margins.The Company recently launched BioNX Regenerative Eye Health & Aesthetics, a new commercial initiative focused on ocular and aesthetic applications.Management remains encouraged by opportunities entering the second half of the year and expects to host an investor update call around September 15, 2026, to discuss operational progress and expectations for the remainder of 2026.

### Related Stocks

- [NXGL.US](https://longbridge.com/en/quote/NXGL.US.md)

## Related News & Research

- [NXGL: Q2 revenue reached $3.69M with a $2.87M net loss; integration and expansion efforts continue](https://longbridge.com/en/news/296106108.md)
- [REG - UIL Limited UIL Finance Ltd - Purchase of 2026 ZDP Shares](https://longbridge.com/en/news/296518280.md)
- [Xcel Energy sets BRL 0.26 per unit distribution for payment Oct. 26, 2026](https://longbridge.com/en/news/296646864.md)
- [Public Storage announces R$ 0.41 per unit dividend for Q3 2026](https://longbridge.com/en/news/296635332.md)
- [Corning sets Q3 2026 dividend at R$ 0.25 per unit](https://longbridge.com/en/news/296635714.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**